OptimizeRx price target lowered to $13 from $18 at Lake Street

Lake Street analyst Eric Martinuzzi lowered the firm’s price target on OptimizeRx to $13 from $18 and keeps a Buy rating on the shares. OptimizeRx posted a disappointing second quarter and lowered its 2023 revenue outlook after suffering from delays related to customers’ legal and regulatory affairs contract review, the analyst tells investors in a research note. The firm does not expect a return to growth until 1Q24.